BioSyent Schedules Fourth Quarter 2017 Earnings Release for March 21, 2018
March 08 2018 - 8:00AM
BioSyent Inc. (“BioSyent”, “the Company”) (TSX Venture:RX) will be
reporting its financial results for the fourth quarter and fiscal
year ended December 31, 2017 on Wednesday, March 21, 2018. A
presentation on the Company’s fourth quarter 2017 results by René
Goehrum, BioSyent President and CEO, will also be available on the
Company’s website on the date of release.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the
trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or
acquiring innovative pharmaceutical and other healthcare products
that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of
patients. BioSyent supports the healthcare professionals that
treat these patients by marketing its products through its
community, hospital and international business units.
As of the date of this press release, the
Company has 14,509,095 common shares issued and outstanding.
For a direct market quote (15 minutes delay) for
the TSX Venture Exchange and other Company financial information
please visit www.tmxmoney.com.
For further information please
contact:
Mr. René C. GoehrumPresident and CEOBioSyent
Inc.Tel: (905) 206-0013E-Mail: investors@biosyent.comWeb:
www.biosyent.com
Biosyent (TSXV:RX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Apr 2023 to Apr 2024